We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 164.80 | 164.80 | 165.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/7/2019 10:06 | Most companies with significant foreign earnings are doing well over the past week - except for VEC whose share price seems to be in a world of its own, not logically influenced by normal commercial factors. | boadicea | |
30/7/2019 09:25 | The market does like round numbers, for now 80 p seems to be a support, it has been both support and resistance numerous times. | diesel | |
25/7/2019 16:53 | I think you are looking at the price far too closely. Set your exit and target and forget about it. I'm running 60 positions across US and Uk markets and if I agonised over every move I'd top myself on a regular basis | davr0s | |
25/7/2019 16:21 | A whole penny shaved off in the last 3 minutes on no volume at all. Ridiculous. | justiceforthemany | |
25/7/2019 10:37 | To me those trades look like sells its only guess work by ADVFN. | pooroldboy55 | |
25/7/2019 10:13 | If you accept that it's HBM selling you could presume it's the broker acting of behalf of HBM executing iceberg trades | frazboy | |
25/7/2019 09:57 | 40K and 25K buy this morning. Other trades are yes very small. Who is drip selling then? If HBM you would think it would be in greater volumes and we would have a holdings RNS. So who is selling 50-100 shares bit by bit and why.... | justiceforthemany | |
25/7/2019 09:36 | Always so disappointing that we cannot ever keep hold of the gains............tak | chrisdgb | |
25/7/2019 09:24 | I'm with you on that Andrew, HBM probably still selling down, and no institutional buyers around. | frazboy | |
25/7/2019 09:12 | Ah the vacancy who are they going to get who has a very good reputation and well paid join VEC with the chance of a takeover however remote and be out on their ear in a year. justfor the problem is no ones buying as simple as that i don't think there is any conspiracy here, just no ones buying as always could well be wrong.Numbers being traded is small very small. A | pooroldboy55 | |
25/7/2019 09:06 | Look at that pitiful 41 trade this morning at 77.1. Well outside the UT and bid price. Makes no sense at all. #corrupt and shorter driven markets. | justiceforthemany | |
25/7/2019 08:33 | insideryou-in a similar vein, why get a real job when there is a vacancy on the board at VEC! | alexchry | |
25/7/2019 07:32 | Why Rob banks with a shot gun when you do it legally with a lap top and a wifi connection without any ramifications | insideryou | |
24/7/2019 22:39 | exactly...until it isn't. That's the chance they are taking but VEC has no CEO right now and so another reason to play it as likely board asleep at the wheel. | polaris | |
24/7/2019 18:46 | Nothing to do with value. Would you not keep playing a slot machine which was 100% predictable? | insideryou | |
24/7/2019 16:42 | Management need to liaise with GSK, Sosei, Hikma and other interested parties and arrange a sale of the company. Years have gone by and the share price has gone nowhere but down. A drop from 190p in 2016 is massive and totally unacceptable. Lilley had to go. | justiceforthemany | |
24/7/2019 16:26 | I dont understand why share price down - GSK numbers were good. Did anybody extract results , which relates to Vectura ? Results : Respiratory Total Respiratory sales were up 21% AER, 17% CER, with strong growth in all regions. Elliptaproduct sales grew 16% AER, 12% CER, with Europe up 28% AER, 29% CER and International up 32% AER, 31% CER on Trelegy Elliptaand Relvar/Breo Elliptagrowth. Nucalawas up 45% AER, 45% CER in Europe and 55% AER, 52% CER in International. In the US, Trelegy Elliptaand Nucalagrowth offset the decline in Relvar/Breo Elliptaon post-generic ICS/LABA price pressure. Sales of Nucalawere £347 million in the six months and grew 42% AER, 37% CER, continuing to benefit from the global rollout of the product. US sales of Nucalagrew 37% AER, 30% CER to £202 million. Sales of Elliptaproducts were up 16% AER, 12% CER to £1,036 million driven by growth in Europe and International. In the US, sales grew 6% AER but were flat at CER, reflecting continued competitive pricing pressures for ICS/LABA products post generic Advair. In Europe, sales grew 28% AER, 29% CER, and in International by 32% AER, 31% CER. Sales of Trelegy Ellipta, our new once daily closed triple product, contributed £207 million globally in the six months, continuing to benefit from the expanded US label. Relvar/Breo Elliptasales were down 9% AER, 11% CER. This was driven by the US decline of 33% AER, 37% CER, impacted by US competitive pricing pressures and the impact of generic Advairon the US ICS/LABA market. In Europe and International, Relvar/Breo Elliptacontinued to grow, up 11% AER, 12% CER, and 22% CER, 20% AER, respectively. | a1ord53 | |
24/7/2019 16:22 | Classic drip drip drip AT action of shorters killing an share price on very low volume. | justiceforthemany | |
24/7/2019 15:40 | The slow drop seems to be gathering pace but on very very low numbers just no buyers in the market, come on Paul get your cheque book out.Bloody hot here today James think I'll have a pinnacle. | pooroldboy55 | |
23/7/2019 18:36 | Remember that most the the analysts have VEC down as loss making, due to the write-offs. I believe that VEC is seriously undervalued just looking at the current business. I don't care much for goodwill and carrying value as they are non-cash balance sheet items that impact the headline number reporting. What they also influence is the ability of VEC to return cash to shareholders by way of a dividend...they can't due to the retained losses generated by the destruction of shareholder value from the merger! It is a vagary of financial accountancy rules. If you look beyond that, strip down the numbers to the basics of ongoing operations and you find that VEC has costs under control, a good long term base product family, some early stage IP with big potential and the cash to develop them. This is not a lost cause money eating machine with some vague hope of a future product in the small pharma arena - and we all know quite a few of those! The leadership has been absent and/or poor for several years and i hope that any new appointment changes that, but the basics are in place. New blood, getting away from the old VEC and SKP management, is a must. If we can get someone with flair then i think they will push the positives. Either that or make the package nice and neat for a takeover in due course that will net them a healthy golden handshake. The ongoing litigation is another turn-off for potential investors. A long, drawn out IP battle with a tier I pharma is not for the faint hearted. Personally, i would love the decision from the judge to come in the next 24 hours and be pro-VEC, just because it is the Q2 GSK numbers tomorrow. A bit of wishful thinking on my part i suspect. VEC do have GSK on the hook for $90M with another $40+M pending judgement. Then there are the future royalties until patent expiry and legal costs to resolve...another 2 or so years in the US jurisdiction territories. All-told it's a possible $200M injection for VEC. The court case is a biggie for VEC but small fry for GSK. Watching intently now for the chart base to be established. I suggested 78 region a while back, which we hit today. Remains to be seen whether that is the floor. | polaris | |
23/7/2019 16:39 | Popper Joe-think you may be right but that money is irrelevant. When the money is distributed the company will be worth less but shareholders will have some cash or the company will have fewer shares in circulation but be worth less, a zero sum game. A disappointment that the company does not know how to use the cash it has generated to develop the business but I suppose that is the result of giving up on R&D. | alexchry | |
23/7/2019 15:59 | I suspect Jimboyce was referring to the proposed tender offer for £50m of shares. Apologies if I am wrong. Unfortunately, buying back 10% of the shares will not necessarily increase the share price of the remaining 90% by 10%. Those remaining 90% will then be shares in a company that has £50m less in the bank than it currently does. Of course, if the tender can clear the overhang from HBM, then Jim's idea of a 10% gift may be an underestimate. | popper joe |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions